Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study

Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture

(2013) Suzanne M. Cadarette et al.   ANNALS OF INTERNAL MEDICINE

Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study

(2009) S.T. Harris et al.   BONE

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®

(2009) John A. Kanis et al.   BONE

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

(2009) A. Abelson et al.   OSTEOPOROSIS INTERNATIONAL

Effectiveness of bisphosphonate therapy in a community setting

(2008) Adrianne C. Feldstein et al.   BONE

Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women

(2008) Julie Blouin et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Fracture Outcomes Related to Persistence and Compliance With Oral Bisphosphonates

(2008) Arlene M Gallagher et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Benefit of Adherence With Bisphosphonates Depends on Age and Fracture Type: Results From an Analysis of 101,038 New Bisphosphonate Users

(2008) Jeffrey R Curtis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effectiveness of antiresorptives for the prevention of nonvertebral low-trauma fractures in a population-based cohort of women

(2008) L. A. Langsetmo et al.   OSTEOPOROSIS INTERNATIONAL

Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday

(2008) J. R. Curtis et al.   OSTEOPOROSIS INTERNATIONAL

Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization

(2008) J. A. Sunyecz et al.   OSTEOPOROSIS INTERNATIONAL

RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction

(2008) J. R. Curtis et al.   OSTEOPOROSIS INTERNATIONAL

Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study

(2008) E. V. McCloskey et al.   OSTEOPOROSIS INTERNATIONAL

Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture

(2008) Sylvie Perreault et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates

(2008) Shonda A Foster et al.   BMC Womens Health